Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada.
The last earnings update was 56 days ago.
Discounted Cash Flow Calculation for OTCPK:INBP using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
Note: Free cash flow to equity valuations ignore the company's cash or debt.
OTCPK:INBP DCF 1st Stage: Next 10 year cash flow forecast
Amount off the current price
is available for.
Share price is
vs Future cash flow value of
Current Discount Checks
to be considered undervalued it must be available for at least 20% below the
current price. Less than 40% is even better.
Integrated BioPharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
Integrated BioPharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Integrated BioPharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Integrated BioPharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Integrated BioPharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Integrated BioPharma's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Integrated BioPharma's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Integrated BioPharma is high growth as no earnings estimate data is available.
Unable to determine if Integrated BioPharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
All data from Integrated BioPharma Company Filings, last reported 3 months ago, and in
Trailing twelve months (TTM)
annual period rather than quarterly.
OTCPK:INBP Past Financials Data
Date (Data in USD Millions)
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
Unable to establish if Integrated BioPharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Examine whether Integrated BioPharma is trading at Integrated BioPharma'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Integrated BioPharma's filings and announcements here.
Integrated BioPharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
4/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Integrated BioPharma's finances.
The net worth of a company is the difference between its assets and liabilities.
Integrated BioPharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Integrated BioPharma's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Integrated BioPharma's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 1.8x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mrs. Riva Kay Sheppard has been Co-Chief Executive Officer of Integrated Biopharma Inc. since May 1, 2019. Mrs. Sheppard served as Executive Vice President at Integrated Biopharma Inc. (aka: Integrated Health Technologies Inc.). since November 2005 until May 1, 2019. Mrs. Sheppard served as President of IHT Properties, Inc. Mrs. Sheppard served as President of Manhattan Drug Company, Inc. Mrs. Sheppard served as Vice President of Integrated Biopharma Inc. from May 1991 to November 2005. She has been Director of Integrated Biopharma Inc. since May 1991. She served as a Director of iBio, Inc. (formerly, iBioPharma, Inc). since December 31, 2007.
Riva's compensation has been consistent with company performance over the past year, both up more than 20%.
Riva's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Integrated BioPharma management team is over 5 years, this suggests they are a seasoned and experienced team.
Founder & Executive Chairman
Co-CEO & Director
Co-CEO & Director
Head of Investor Relations
Chief Scientific Officer of iBioPharma
Chief Executive Officer of Nucycle Therapy Inc and President of Nucycle Therapy Inc
President of Nutraceutical Segment
President of iBioPharma
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Integrated BioPharma board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
Founder & Executive Chairman
Co-CEO & Director
Co-CEO & Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. It operates through three segments: Contract Manufacturing, Branded Proprietary Products, and Other Nutraceutical Businesses. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized healthcare providers. The Branded Proprietary Products segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep, Green Envy, FiberCal, and Wheatgrass brands, as well as other branded proprietary nutraceutical products. The Other Nutraceutical Businesses segment sells private label vitamin and nutritional supplement products through the Internet; and distributes fine natural botanicals, including multi minerals, as well as raw materials. This segment also provides warehousing and fulfilment services. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was founded in 1979 and is based in Hillside, New Jersey.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.